Factor works with strategic partners to develop and advance products based on our technologies to the clinic. Factor’s technologies have the potential to contribute to new therapeutic products, many of which will require testing in clinical trials. As a result, Factor collaborates with companies that have extensive experience in all stages of the therapeutic product development pipeline.
Pictured from right to left: Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc.; Gregory Fiore, M.D., Co-Founder and CEO of Exacis Biotherapeutics Inc.; Christopher Rohde, Ph.D., Co-Founder and Chief Technology Officer of Factor Bioscience Inc.
Eterna Therapeutics Inc. (Nasdaq: ERNA) is a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines. Eterna has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing proteins, and the ToRNAdo™ mRNA delivery system from Factor Bioscience.
Acquired in 2021 by Eterna Therapeutics Inc. (Nasdaq: ERNA), Novellus was founded by the Factor team to develop therapeutic products based on Factor's technologies. Novellus is focused on developing advanced mesenchymal stem cell ("MSC")-based therapies to treat a broad range of disease indications.
Founded in 2020 by the Factor team, Exacis is using Factor's technologies to develop advanced T-cell and NK-cell therapies to treat cancer.
CÚRAM is the Science Foundation Ireland Centre for Research in Medical Devices, based at the National University of Ireland, Galway. CÚRAM’s innovative approach incorporates biomaterials, drug delivery, cell-based technologies, glycosciences and device design to enhance, develop and validate both traditional and new combinational medical devices from molecular design stage to implant manufacturing. Factor is currently sponsoring multiple collaborative research projects at CÚRAM focused on next-generation mRNA and engineered cell therapies.
Erigen LLC was founded by the Factor team to provide cell and nucleic-acid research services, including the creation of custom cell and tissue disease models. For more information on Erigen’s capabilities and portfolio of services, contact: info@erigen.com.
Eterna Therapeutics Inc. (Nasdaq: ERNA) is a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines. Eterna has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing proteins, and the ToRNAdo™ mRNA delivery system from Factor Bioscience.
Acquired in 2021 by Eterna Therapeutics Inc. (Nasdaq: ERNA), Novellus was founded by the Factor team to develop therapeutic products based on Factor's technologies. Novellus is focused on developing advanced mesenchymal stem cell ("MSC")-based therapies to treat a broad range of disease indications.
Founded in 2020 by the Factor team, Exacis is using Factor's technologies to develop advanced T-cell and NK-cell therapies to treat cancer.
CÚRAM is the Science Foundation Ireland Centre for Research in Medical Devices, based at the National University of Ireland, Galway. CÚRAM’s innovative approach incorporates biomaterials, drug delivery, cell-based technologies, glycosciences and device design to enhance, develop and validate both traditional and new combinational medical devices from molecular design stage to implant manufacturing. Factor is currently sponsoring multiple collaborative research projects at CÚRAM focused on next-generation mRNA and engineered cell therapies.
Erigen LLC was founded by the Factor team to provide cell and nucleic-acid research services, including the creation of custom cell and tissue disease models. For more information on Erigen’s capabilities and portfolio of services, contact: info@erigen.com.